---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-000467"
form_type: "8-K/A"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T07:55:42.418316+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics files audited FY2023 financials of acquired Opus Inc.; net loss $9.75M, cash $180k

## Summary
- FY2023 audited: net loss $9.75M, no revenue; accumulated deficit $25.1M.
- Cash & equivalents only $0.18M at Dec 31, 2023; total liabilities $2.93M exceed assets $0.79M.
- R&D spending $7.18M, G&A $2.72M; convertible notes and warrant liabilities of $1.12M at fair value.
- Acquisition closed Oct 22, 2024; combined company renamed Opus Genetics, Inc. (ticker IRD).

## SEC filing metadata
- accession: 0001140361-25-000467
- form_type: 8-K/A
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125000467/0001140361-25-000467-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125000467/ef20041180_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-000467
- JSON: https://secwatch.observer/filing/0001140361-25-000467.json
- Plain text: https://secwatch.observer/filing/0001140361-25-000467.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.